Estrogen Receptor Positive Breast Cancer - tamoxifen - RFC3 overexpression + ER positive

Association details:

Biomarker:	RFC3 overexpression + ER positive
Cancer:	Estrogen Receptor Positive Breast Cancer
Drug:	tamoxifen (Estrogen receptor antagonist)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: D – Preclinical

Source:

Aging (Albany NY)

Title:

Involvement of RFC3 in tamoxifen resistance in ER-positive breast cancer through the cell cycle

Published date:

12/06/2023

Excerpt:

CONTRADICTING EVIDENCE: Using the CC-K8 assay, it was found that the proliferation rate of RFC3-overexpressing MCF-7 cells was significantly increased compared to that of the control group, and the inhibitory effect of tamoxifen on the proliferation of RFC3-overexpressing MCF-7 cells was diminished compared to that of the control group...